What happened to idgx stock in 2015?
(IDGX) raised $60 million in an initial public offering (IPO) on Wednesday, February 11th 2015. The company issued 4,600,000 shares at $12.00-$14.00 per share. Citigroup and Jefferies acted as the underwriters for the IPO and William Blair and Cantor Fitzgerald were co-managers.
Does altheadx stock grow dividends?
AltheaDx does not have a long track record of dividend growth. In the past three months, AltheaDx insiders have not sold or bought any company stock. Who are AltheaDx's key executives? What other stocks do shareholders of AltheaDx own?
What is idgenetix pharmacogenetic testing?
The Company's IDgenetix pharmacogenetic testing portfolio addresses various clinical conditions in the United States, including cardiovascular disease, neuropsychiatric disorders and pain. The IDgenetix testing process consists of three steps: drug metabolism genotyping, drug response genotyping and algorithm screening.
What is the ticker symbol for Altheadx?
What other stocks do shareholders of AltheaDx own?
AltheaDx trades on the NASDAQ under the ticker symbol "IDGX."
What is AltheaDX?
Based on aggregate information from My MarketBeat watchlists, some companies that other AltheaDx investors own include Broadcom (AVGO), Celsion (CLSN), NIO (NIO), Electrameccanica Vehicles (SOLO), Workhorse Group (WKHS), Walmart (WMT), Achillion Pharmaceuticals (ACHN), Acer Therapeutics (ACER), Aurora Cannabis (ACB) and American Airlines Group (AAL).
Does AltheaDX pay dividends?
AltheaDx, Inc. is a United States-based commercial-stage molecular diagnostics company. The Company is specialized in the field of pharmacogenetics. The Company focuses on enabling physicians, managed care organizations, pharmaceutical companies and other healthcare entities to make personalized therapeutic decisions for patients. The Company's IDgenetix pharmacogenetic testing portfolio addresses various clinical conditions in the United States, including cardiovascular disease, neuropsychiatric disorders and pain. The IDgenetix testing process consists of three steps: drug metabolism genotyping, drug response genotyping and algorithm screening. Its algorithm-based bioinformatic platform and pharmacogenetics product testing portfolio are intended to serve as a tool to assist healthcare providers in identifying optimal drugs for their patients, as well as dosing guidelines based on a patient's genetic make-up, prescription regimen and other key factors.
Interpace Biosciences Terminates Rights Offering Announces Change in CMS Medicare Reimbursement of its Thyroid Tests
AltheaDx does not currently pay a dividend.
Interpace Biosciences Announces Appointment of Vijay Aggarwal, Ph.D. as New Director
PARSIPPANY, NJ, Jan. 28, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (OTCQX: IDXG) (“Interpace” or the “Company”) a leader in enabling personalized medicine, announced today that it was terminating its previously announced rights offering and the mutual termination of the standby purchase agreement with 3K Limited Partnership.
AltheaDx (NASDAQ:IDGX) Price Target and Consensus Rating
PARSIPPANY, NJ, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences , Inc. (OTCQX: IDXG) (“Interpace”) a leader in enabling personalized medicine, is pleased to announce today that Vijay Aggarwal, Ph.D., has been appointed to the Interpace Board of Directors effective February 1, 2022. Dr. Aggarwal replaces Eric B.
Analyst Ratings By Month
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy).
Average Share Price and Price Target by Month
The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
AltheaDx (NASDAQ:IDGX) Analyst Ratings Frequently Asked Questions
The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target.
